SCHEMBL2770569

SCHEMBL2770569

Cc1cc(OCc2c(C(C)C)cnn2-c2c(Cl)cccc2Cl)ccc1N

nearest known ligand 0.56

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
NR1H4 Q96RI1 5/20 0.56
NPC1 O15118 2/20 0.38
RAB9A P51151 2/20 0.38
MAPT P10636 1/20 0.38
HTT P42858 1/20 0.38
L3MBTL1 Q9Y468 1/20 0.38
MAPK14 Q16539 8/20 0.35
NPBWR1 P48145 1/20 0.34
MCHR1 Q99705 1/20 0.34
HTR1A P08908 1/20 0.32
DRD2 P14416 1/20 0.32
HTR2A P28223 1/20 0.32
HTR7 P34969 1/20 0.32
HTR6 P50406 1/20 0.32
HPGD P15428 1/20 0.32
SMN1; SMN2 Q16637 1/20 0.32
MRGPRX4 Q96LA9 1/20 0.32
SRC P12931 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2770298 0.90 NR1H4 (0.56) NR1H4MAPTMAPK14NPBWR1MCHR1
SCHEMBL2770725 0.88 NR1H4 (0.54) NR1H4NPC1RAB9AMAPK14NPBWR1
SCHEMBL2771111 0.88 NR1H4 (0.58) NR1H4L3MBTL1NPBWR1MCHR1SMN1; SMN2
SCHEMBL2773824 0.86 NR1H4 (0.56) NR1H4MAPK14NPBWR1MCHR1MRGPRX4
SCHEMBL2770727 0.86 NR1H4 (0.54) NR1H4NPC1RAB9AMAPK14NPBWR1
SCHEMBL2770621 0.86 NR1H4 (0.51) NR1H4HTTL3MBTL1MAPK14NPBWR1
SCHEMBL2771331 0.85 NR1H4 (0.53) NR1H4MRGPRX4
SCHEMBL2772049 0.85 NR1H4 (0.62) NR1H4NPC1RAB9AMAPTMAPK14
SCHEMBL2770222 0.85 NR1H4 (0.56) NR1H4L3MBTL1NPBWR1MCHR1MRGPRX4
SCHEMBL3764857 0.84 NR1H4 (0.55) NR1H4NPC1RAB9AMAPTMAPK14

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7846960-B2 FXR agonists ELI LILLY AND COMPANY (US) 2010-12-07 US disclosed
EP-2029547-B1 FXR AGONISTS LILLY CO ELI (US) 2010-04-28 EP disclosed
US-20090270460-A1 FXR AGONISTS JPMORGAN CHASE BANK, N.A., AS SUCCESSOR COLLATERAL AGENT 2009-10-29 US disclosed
EP-2029547-A1 FXR AGONISTS ELI LILLY AND COMPANY (US) 2009-03-04 EP disclosed
WO-2007140183-A1 FXR AGONISTS ELI LILLY AND COMPANY (US) 2007-12-06 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090270460-A1 FXR AGONISTS NR1H4, SLC10A1, GPBAR1 NR1H4 1/4885NPC1 37/4885RAB9A 1716/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.